乙功能化免疫糖用于准β-葡萄糖脑糖酶调节的向
Maria Giulia Davighi1, Francesca Clemente1, Camilla Matassini1
1Department of Chemistry "Ugo Schiff" (DICUS), Via della Lastruccia 3-13, 50019 Sesto F.no (FI), Italy.
European journal of medicinal chemistry
|April 2, 2025
概括
新的pH敏感药物输送系统针对个性化医疗的酸性环境. 这些系统提高了对高氏病和帕金森病的治疗疗效.
科学领域:
- 生物化学 生物化学
- 药物运输 药物运输 药物运输
- 个性化医疗是个性化的医疗.
背景情况:
- lysosomal酶β-glucocerebrosidase (GCase) 的功能障碍与高氏病和帕金森病有关.
- 目前用于GCase的药理伴随剂 (PC) 由于在溶解体中与酶分离不良,其疗效有限.
- 氧化应激是高氏病和帕金森病发病的一个重要因素.
研究的目的:
- 开发新的pH敏感药物输送系统,以加强GCase稳定和向治疗.
- 设计在酸性溶酶体环境中解离的化合物,改善治疗结果.
- 结合抗氧化剂部分来对抗与GCase相关疾病相关的氧化应激.
主要方法:
- 合成pH敏感的乙功能化免疫糖,其中包含抗氧化剂部分 (甲基和素).
- 在ex vivo纤维细胞试验中评估pH敏感度和GCase稳定性.
- 在细胞溶解物和完整细胞中验证化合物的疗效.
主要成果:
- 1-4的化合物表现出不同程度的pH敏感性和GCase稳定性.
- 乙4表现出有希望的pH依赖解离和GCase稳定性质.
- 合成的化合物在细胞溶解物和完整细胞模型中得到了验证.
结论:
- 对于pH敏感的乙功能化免疫糖是一种有前途的策略,用于针对性药物输送在溶酶体储存障碍.
- 开发的系统有效地利用酸性环境来控制药物释放和解离.
- 乙4通过稳定GCase和减少氧化应激,显示出对高氏病和帕金森病的治疗干预的潜力.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
128
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
128
Oligosaccharide Assembly
2.7K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
2.7K
Glucagon-like Receptor Agonists
272
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272
Insulin: Biosynthesis, Chemistry, and Preparation
322
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
322
Dipeptidyl Peptidase 4 Inhibitors
140
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
140
Oral Hypoglycemic Agents: Glinides
114
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
114


